Гепатокоморбидность при псориазе
https://doi.org/10.33667/2078-5631-2021-9-7-11
Аннотация
К широко известным проявлениям при псориазе относят псориатический артрит и псориаз ногтей, однако в настоящее время стали активно изучаться и другие коморбидные псориазу состояния, такие как заболевания печени, сахарный диабет, заболевания сердечно-сосудистой системы, ожирение, психические расстройства, воспалительные заболевания кишечника и суставов. Помимо схожих иммунологических механизмов, обнаружены гены, общие для псориаза и встречающихся при нем коморбидных заболеваний. В статье приводятся данные о нарушениях функции гепатобилиарной системы у больных псориазом. Раскрываются результаты исследований зарубежных и отечественных авторов, показавшие значимые связи тяжести поражения печени при псориазе.
Об авторе
М. А. Королева
ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента России
Россия
Россия
Королева Мария Александровна, врач-дерматовенеролог, зав. кабинетом
Список литературы
1. Олисова О. Ю. Псориаз: эпидемиология, патогенез, клиника, лечение. Consilium Medicum. Дерматология. 2010; 4: 3–8.
2. Кочергин Н. Г., Смирнова Л.Н, Потекаев Н. Н., Билалова У. Г. Псориаз: комор-бидности и комедикации.-Врач 2009; 5: 15–20.
3. Li K., Armstrong A. W. A review of health outcomes in patients with psoriasis. Dermatol. Clin. 2012; 30 (1): 61–72.
4. Griffiths C. E., Barker J. N. Pathogenesis and clinical features of psoriasis.Lancet. 2007; 370 (9583): 263–71.
5. Azfar R. S., Gelfand J. M. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr. Opin. Rheumatol. 2008; 20 (4): 416–22.
6. Gustafson B., Hammarstedt A., Andersson C. X., Smith U. Inflamed adipose tissue a culprit underlying the metabolic syndrome and atherosclerosis. Ar-terioscler. Thromb. Vasc. Biol. 2007; 27 (11): 2276–83.
7. Yoo H., Kim S. J., Kim Y., Lee H., Kim T. Y. Insulin-like growth factor-II regulates the 12-lipoxygenase gene expression and promotes cell proliferation in human keratinocytes via the extracellular regulatory kinase and phosphatidylinositol 3-kinase pathways. Int. J. Biochem. Cell Biol. 2007; 39 (6): 1248–59.
8. Zaina S., Nilsson J. Insulin-like growth factor II and its receptors in atherosclerosis and in conditions predisposing to atherosclerosis. Curr. Opin. Lipidol. 2003; 14 (5): 483–9.
9. Eckel R. H., Grundy S. M., Zimmet P. The metabolic syndrome. Lancet.2005; 365 (9468): 1415–28
10. Sommer D. M., Jenisch S., Suchan M., Christophers E., Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch. Dermatol. Res. 2007; 298 (7): 321–8.
11. Langan S. M., Seminara N. M., Shin D. B., Troxel A. B., Kimmel S. E., Mehta N. N., et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J. Invest. Dermatol. 2012; 132 (3): 556–62.
12. Rozumbaeva L. P., Kozlova I. V., Bakulev A. L., Bykova A. P. Clinical and instrumental features of the hepatobiliary system in psoriasis. Experimental and Clinical Gastroenterology. Russian Journal (Eksperimentalnaya i klin-icheskaya gastroehnterologiya). 2014; (2): 64. (in Russian).
13. Smirnov A. V., Barilo A. A., Smolnikova V. A. Diseases of the hepatobiliary system as predictors of the progression of psoriasis. Herald of the Russian Academy of Medical Sciences. Russian Journal (Vestnik Rossiyskoy akademii meditsinskikh nauk). 2016; 71 (2): 102–8. (in Russian).
14. Miele L., Vallone S., Cefalo C., La Torre G., Di Stasi C., Vecchio F. M., Pompili M. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009; 51 (4): 778–8.
15. Lonardo A., Loria P., Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI. ST. E.N.A. study. Dig. Liver Dis. 2001; 33 (1): 86–7.
16. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatology. 1986; 172 (6): 298–30.
17. Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, D’Agostino M, Gabrieli ML, Vero V, Biolato M, Pompili M, Gasbarrini G, Rapaccini G, Amerio P, De Simone C, Grieco A. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. J. Jepatol, 2009, 51 (4): 778–786.
18. Gisondi P., Tessari G., Conti A. et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital- based case-control study. Br. J. Dermatol. 2007. – Vol. 157 (1). P. 68–73.
19. Batani A, Brănişteanu DE, Ilie MA, Boda D, Ianosi S, Ianosi G, Caruntu C. Assessment of dermal papillary and micro- vascular parameters in psoriasis vulgaris using in vivo reflectance confocal microscopy in vivo. Exp Ther Med, 2018, 15 (2): 1241–1246.
20. Леру П. М. Лекарственная аллергия в практике первичной медико-санитарной помощи в Румынии: анкетный опрос. Аллергия, астма Клиническая Иммунология, 2014, 10 (1): 16.
21. Ianoşi SL, Forsea AM, Lupu M, Ilie MA, Zurac S, Boda D, Ianosi G, Neagoe D, Tutunaru C, Popa CM, Carunto C. Role of modern imaging techniques for the in vivo diagnosis of lichen planusExp Ther Med, 2018, 17 (2): 1052–1060.
22. Сzernichow S, Kengne AP, Huxley RR, Batty GD, de Galan B, Grobbee D, Pillai A, Zoungas S, Marre M, Woodward M, Neal B, Chalmers J. ADVANCE Collaborative Group.Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE. Eur J Cardiovasc Prev Rehabil, 2011, 18 (2): 312–319.
23. Kahn HS. The ‘lipid accumulation product’ performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord, 2005, 5: 26.
24. Anstee Q. M., Targer G., Day C. P. Nature Reviews Gastroenterology & Hepatology 2013; 10 (6): 330–344.
25. Бирн К. Д., Таргер Г. НАЖБП: мультисистемное заболевание. Journal of Hepatology 2015; 62 (1): S 47–S 64.
26. Gisondi P, Targer G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaques psoriasis. J Hepatol. 2009; 51 (4): 758.
27. Michael H Le, Pardha Devaki, Nghiem B Ha, Dae Won Jun, Helen S Te, Ramsey C Cheung, Mindie H Nguyen Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. 2017; 12: e0173499.
28. Shira Zelber-Sagi, Dorit Nitzan-Kaluski, Zamir Halpern, Ran Oren. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measuresInt. 2006; 26: 856–63.
29. Xin Xu, Lina S, Yunlu Gao, Yangfeng Ding. The Prevalence of Nonalcoholic Fatty Liver Disease and Related Metabolic Comorbidities Was Associated with Age at Onset of Moderate to Severe Plaque Psoriasis: A Cross-Sectional Study 2017; 12: e0169952.
30. Roberts K. K., Cochet A. E., Lamb P. B. et al. Th e preva-lence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Th er, 2015, No. 41, pp. 293–300.
31. R. Candia, A. Ruiz, R. Torres-Robles, N. Chávez-Tapia, N. Méndez-Sánchez, M. Arrese. ‘Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis’ J. Eur Acad Dermatol Venereol. 2015; 29: 656–62.
32. Alessandro Mantovani, Paolo Gisond [OrcID], Amedeo Lonardo [OrcID] and Giovanni TargherRelationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis? Int J Mol Sci. 2016; 17: 217.
33. Ганцетти Г., Кампанати А, Оффидани А. Неалкогольная жировая болезнь печени и псориаз. 2015; 7: 315–26.
34. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. 2010; 6: 175–8.
35. B Cronstein. How does methotrexate suppress inflammation? Clin Exp Rheumatol. Epub 2010 Oct 28 2010; 28 (5 Suppl 61): S 21–3.
36. Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389: 528–37.
37. Peng Z, Fernandez P, Wilder T, et al. 2008; 27: 821–4.
38. Peng Z, Borea PA, Varani K, et al. Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest. 2009; 119: 582–94.
39. В. Kaplowitz N, DeLeve LD, editors. Drug-induced liver injury. Academic Press; 2013. Pp. 593–604.
40. O’Rourke RA, Eckert GE. Methotrexate-induced hepatic injury in an adult. A case report. Arch Intern Med. 1964; 113: 191–4.
41. Shetty A, Cho W, Alazawi W, Syn WK. Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease.Am J Med Sci. 2017; 354: 172–81.
42. Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: National Conference of the Psoriasis Foundation 2009. J Am Acad Dermatol. 2009; 60: 824–37.
43. Nast A, Jacobs A, Rosumeck S, Werner R. Methods Report: European S 3-Guidelines on the systematic treatment of psoriasis vulgaris-update 2015-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015; 29: e1–22.
44. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. 2006; 26: 55–62.
45. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford). 2009 May; 48 (5): 569–72.
46. Wenk K S, Arrington K C, Ehrlich A. Psoriasis and non-alcoholic fatty liver disease 2011; 25: 383–91.
47. An J, Zhang D, Wu J и др. The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis. Pharmacol Res. 2017; 121: 158–68.
48. Szepietowski J, Adamski Z, Chodorowska G, et al. Psoriasis. Diagnostic and therapeutic recommendations of the polish dermatological society. Part II: Moderate to severe psoriasis. Dermatol Rev. 2014;101: 455–72.
49. Rossi RE, Parisi I, Despott EJ. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World J Gastroenterol. Dec 14, 2014; 20 (46): 17352–17359.
50. Rossi RE, Parisi I, Despott EJ, Burroughs AK, O’Beirne J, Conte D, Hamilton MI, Murray CD. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World J Gastroenterol 2014; 20 (46): 17352–17359. PMID: 25516646. DOI: 10.3748/wjg.v20.i46.17352.
51. Rossi RE, Parisi I, Despott EJ, Burroughs AK, O’Beirne J, Conte D, Hamilton MI, Murray CD. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World J Gastroenterol 2014; 20 (46): 17352–17359. PMID: 25516646. DOI: 10.3748/wjg.v20.i46.17352] 2014;20:17352–9.
52. Rossi RE, Parisi I, Despott EJ, Burroughs AK, O’Beirne J, Conte D, Hamilton MI, Murray CD. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World J Gastroenterol 2014; 20 (46): 17352–17359. PMID: 25516646. DOI: 10.3748/wjg.v20.i46.17352.
53. Carrascosa JM, Bonanad C, Dauden E. Psoriasis and Nonalcoholic Fatty Liver Disease Actas Dermo-Sifiliográficas. 2017; 108: 506–14.
54. Stanley TL, Zanni MV, Johnsen S. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011; 96: E 146–50.
55. Agata N Burska, Rajalingham Sakthiswary, Naveed Sattar. Effects of Tumour Necrosis Factor Antagonists on Insulin Sensitivity/Resistance in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. 2015; 10: e0128889.
56. Gisondi P, Galvan A, Idolazzi L, Girolomoni G. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med. 2015; 2: 1.57. Nast A, Jacobs A, Rosumeck S, Werner R. Methods Report: European S 3-Guidelines on the systematic treatment of psoriasis vulgaris-update 2015-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015; 29: e1–22.
57. Feagins LA, Flores A, Arriens C. Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. European Journal of Gastroenterology & Hepatology. 2015; 27: 1154–60.
Рецензия
Для цитирования:
Королева М.А. Гепатокоморбидность при псориазе. Медицинский алфавит. 2021;(9):7-11. https://doi.org/10.33667/2078-5631-2021-9-7-11
For citation:
Koroleva M.A. Hepatocorbidity in psoriasis. Medical alphabet. 2021;(9):7-11. (In Russ.) https://doi.org/10.33667/2078-5631-2021-9-7-11
Просмотров:
283
Послать статью по эл. почте 